1
|
Yun Y, Mun S, Lee S, Kang HG, Lee J. Serum L-selectin levels as predictive markers for chronic major depressive disorder progression. Ann Gen Psychiatry 2024; 23:37. [PMID: 39415236 PMCID: PMC11481545 DOI: 10.1186/s12991-024-00522-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Accepted: 10/07/2024] [Indexed: 10/18/2024] Open
Abstract
BACKGROUND Major depressive disorder (MDD) exhibits a recurrence rate of up to 70%. Frequent recurrence can lead to chronic depression, which has considerable personal and societal consequences. This study aims to identify a serum protein biomarker to predict MDD recurrence and progression to chronicity. METHODS Serum samples from the MDD with single episode group (MDD-S), MDD with recurrence group (MDD-R), and a healthy control group were collected. Non-targeted analysis of the serum proteome was conducted using liquid chromatography-tandem mass spectrometry. Statistically significant common proteins when comparing the three groups were chosen. The selected marker candidates were subsequently validated through multiple response monitoring (MRM), incorporating a healthy control, MDD-S, MDD-R(2) (two episodes), and MDD-R(> 2) (more than two episodes) groups. RESULTS L-selectin levels showed an upward trend in the MDD-R group compared to the healthy control and MDD-S groups. MRM validation revealed a decreased tendency for L-selectin in the MDD-R(> 2) group, indicative of a chronic state, versus the healthy control and MDD-S groups. The receiver operating characteristic analysis highlighted L-selectin as the chosen biomarker due to its classification efficacy for the MDD-R(> 2) group. CONCLUSION L-selectin emerged as a predictive biomarker for MDD recurrence and its potential evolution into chronic depression. This marker offers insights into changes in leukocyte-mediated inflammatory responses characteristic of chronic depression. Consequently, it may forecast the transition from acute to chronic inflammation in depressive patients.
Collapse
Affiliation(s)
- Yeeun Yun
- Department of Biomedical Laboratory Science, Graduate School, Eulji University, Gyeonggi, Republic of Korea
| | - Sora Mun
- Department of Biomedical Laboratory Science, College of Health Science, Eulji University, Gyeonggi, Republic of Korea
| | - Seungyeon Lee
- Department of Senior Healthcare, Graduate School, Eulji University, Gyeonggi, Republic of Korea
| | - Hee-Gyoo Kang
- Department of Biomedical Laboratory Science, Graduate School, Eulji University, Gyeonggi, Republic of Korea.
- Department of Biomedical Laboratory Science, College of Health Science, Eulji University, Gyeonggi, Republic of Korea.
- Department of Senior Healthcare, Graduate School, Eulji University, Gyeonggi, Republic of Korea.
| | - Jiyeong Lee
- Department of Biomedical Laboratory Science, Graduate School, Eulji University, Gyeonggi, Republic of Korea.
- Department of Biomedical Laboratory Science, College of Health Science, Eulji University, Gyeonggi, Republic of Korea.
| |
Collapse
|
2
|
Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, Blalock JA, Beneventi D, Morris C, Karam-Hage M. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety 2022; 39:429-440. [PMID: 35535436 PMCID: PMC9705120 DOI: 10.1002/da.23259] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 04/08/2022] [Indexed: 11/07/2022] Open
Abstract
IMPORTANCE Improving treatment outcomes for smokers with major depressive disorder (MDD) can have significant public health implications. OBJECTIVE To evaluate the safety and efficacy of smoking cessation pharmacotherapy among smokers with MDD. DESIGN Secondary analysis of a randomized, double-blind, active- (nicotine patch) and placebo-controlled trial of 12 weeks of either varenicline or bupropion with a 12-week follow-up. PARTICIPANTS Community volunteers 18-75 years of age; smoke 10+ cigarettes/day; with clinically stable MDD (N = 2635) or no psychiatric disorder (N = 4028), from 140 sites in 16 countries. INTERVENTION Twelve weeks of pharmacotherapy (placebo [PLA], nicotine replacement therapy [NRT], bupropion [BUP], varenicline [VAR]) plus brief cessation counseling. MEASURE(S) Primary safety outcome: the occurrence of ≥1 treatment-emergent, moderate to severe neuropsychiatric adverse event (NPSAE). Primary efficacy outcome: biochemically confirmed continuous abstinence (CA) during the final 4 weeks of treatment (Weeks 9-12). RESULTS A total of 6653 participants (56% female; 39% MDD) ~47 years old. Risk of NPSAEs did not differ by medication for MDD. MDD had higher risk (p < .0001) for NPSAEs than the NPC. Efficacy (6653; intent-to-treat): CA rates for MDD versus NPC respectively were 31.2% versus 38.0% VAR; 23.0% versus 26.1% BUP; 22.6% versus 26.4% NRT; and 13.4% versus 13.7% PLA but no differential treatment effect was noted within the cohorts. All active treatments differed from PLA but VAR showed the largest effect. CONCLUSIONS Results suggest that for MDD smokers, inclusive of those with recurrent episode, varenicline plus counseling may be the best pharmacological option for the treatment of smoking given its greater efficacy effect size and similar risk of NPSAEs. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01456936. https://clinicaltrials.gov/ct2/show/NCT01456936.
Collapse
Affiliation(s)
- Paul M. Cinciripini
- Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - George Kypriotakis
- Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Charles Green
- Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX, USA
| | | | - Robert M. Anthenelli
- Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA
| | - Jennifer Minnix
- Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Janice A. Blalock
- Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Diane Beneventi
- Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chad Morris
- Department of Psychiatry, University of Colorado, Aurora, CO, USA
| | - Maher Karam-Hage
- Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
3
|
Varghese S, Frey BN, Schneider MA, Kapczinski F, de Azevedo Cardoso T. Functional and cognitive impairment in the first episode of depression: A systematic review. Acta Psychiatr Scand 2022; 145:156-185. [PMID: 34758106 DOI: 10.1111/acps.13385] [Citation(s) in RCA: 41] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 10/27/2021] [Accepted: 11/07/2021] [Indexed: 12/11/2022]
Abstract
OBJECTIVES To describe the cognitive and functional impairment in individuals with the first episode of major depressive disorder (MDD) as compared to controls and individuals with recurrent MDD. Also to describe the functional and cognitive trajectory after the first episode of MDD. METHODS A total of 52 studies were included in our systematic review. 32 studies compared the cognitive performance between first episode of depression (FED) and controls, 11 studies compared the cognitive performance between recurrent depression (RD) and FED, 10 compared global functioning between RD and FED, four studies assessed cognition in FED over time, and two studies assessed global functioning in FED over time. RESULTS The majority of studies (n = 22/32, 68.8%) found that FED subjects performed significantly worse than controls on cognitive tests, with processing speed (n = 12) and executive/working memory (n = 11) being the most commonly impaired domains. Seven out of 11 studies (63.6%) found that RD performed significantly worse than FED, with verbal learning and memory being the most commonly impaired domain (n = 4). Most studies (n = 7/10, 70%) did not find a significant difference in global functioning between RD and FED. In three of four longitudinal studies assessing cognition, subgroup analyses were used instead of directly assessing cognition in FED over time while the remaining study found significant cognitive declines over time in FED when compared to controls. The two longitudinal studies assessing functional trajectory found that functioning significantly improved over time, possibly due to the improvement of depressive symptoms. CONCLUSION There is strong evidence that cognitive impairment is present during the first episode of depression, and individuals with multiple episodes display greater cognitive impairment than individuals with a single episode. Future studies aimed at identifying predictors of cognitive and functional impairment after the first episode of depression are needed to describe the functional and cognitive trajectory of individuals with the first episode of MDD over time.
Collapse
Affiliation(s)
- Shawn Varghese
- Undergraduate Medical Education (UGME), McMaster University, Hamilton, Ontario, Canada
| | - Benicio N Frey
- Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
| | - Maiko A Schneider
- Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.,Youth Wellness Centre, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
| | - Flavio Kapczinski
- Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.,Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Rio Grande do Sul, Brazil.,Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.,Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
| | - Taiane de Azevedo Cardoso
- Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
4
|
Serafini G, Santi F, Gonda X, Aguglia A, Fiorillo A, Pompili M, Carvalho AF, Amore M. Predictors of recurrence in a sample of 508 outpatients with major depressive disorder. J Psychiatr Res 2019; 114:80-87. [PMID: 31051436 DOI: 10.1016/j.jpsychires.2019.04.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 04/15/2019] [Accepted: 04/18/2019] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Specific predictors of relapse/recurrence in major depressive disorder (MDD) have been identified but evidence across studies are inconsistent. This study aimed to identify the most relevant socio-demographic/clinical predictors of MDD recurrence in a sample of 508 outpatients. METHODS This naturalistic cohort study included 508 currently euthymic MDD patients (mean age = 54.1 ± 16.2) of which 53.9% had a single and 46.1% recurrent depressive episodes. A detailed data collection was performed and illness histories were retraced through clinical files and lifetime computerized medical records. RESULTS Compared to patients with single episode, MDD patients with recurrent episodes significantly differ regarding current age, gender, working status, positive history of psychiatric disorders in family, first-lifetime illness episode characteristics, first-episode and current psychotic symptoms, current melancholic features and seasonality, age at first treatment, duration of untreated illness, and comorbid cardiovascular/endocrinological conditions. However, after multivariate analyses controlling for current age, gender, educational level, working status differences, psychiatric conditions in family, and age of illness episode, recurrence was associated with older age (p ≤ .001), younger age at first treatment (p ≤ .005), being treated with previous psychoactive treatments (p .001), and longer duration of untreated illness (p .001). CONCLUSIONS The variables associated with MDD recurrence identified in the current study may aid in the stratification of patients who could benefit from more intensive maintenance treatments for MDD. However, clinicians should rapidly identify cases that are not likely to recur in order to avoid unnecessary treatments which are commonly considered as the standard of care.
Collapse
Affiliation(s)
- Gianluca Serafini
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
| | - Francesca Santi
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - Xenia Gonda
- Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary; MTA-SE Neuropsychopharmacology and Neurochemistry Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary; NAP-2-SE New Antidepressant Target Research Group, Semmelweis University, Budapest, Hungary
| | - Andrea Aguglia
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - Andrea Fiorillo
- Department of Psychiatry, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - Maurizio Pompili
- Department of Neurosciences, Suicide Prevention Center, Sant'Andrea Hospital, University of Rome, Rome, Italy
| | - André F Carvalho
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Mario Amore
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| |
Collapse
|
5
|
Evins AE, Benowitz NL, West R, Russ C, McRae T, Lawrence D, Krishen A, St. Aubin L, Maravic MC, Anthenelli RM. Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. J Clin Psychopharmacol 2019; 39:108-116. [PMID: 30811371 PMCID: PMC6488024 DOI: 10.1097/jcp.0000000000001015] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest. METHODS We performed secondary analyses of safety and efficacy outcomes by psychiatric diagnosis in EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a 12-week, randomized, double-blind, triple-dummy, placebo- and active (NRT)-controlled trial of varenicline and bupropion with 12-week follow-up, in a subset population, n = 4092, with a primary psychotic (n = 390), anxiety (n = 792), or mood (n = 2910) disorder. Primary end-point parameters were incidence of prespecified moderate and severe neuropsychiatric adverse events (NPSAEs) and weeks 9 to 12 continuous abstinence rates (9-12CAR). RESULTS The observed NPSAE incidence across treatments was 5.1% to 6.3% in those with a psychotic disorder, 4.6% to 8.0% in those with an anxiety disorder, and 4.6% to 6.8% in those with a mood disorder. Neither varenicline nor bupropion was associated with significantly increased NPSAEs relative to NRT or placebo in the psychiatric cohort or any psychiatric diagnostic subcohort. There was a significant effect of treatment on 9-12CAR (P < 0.0001) and no significant treatment-by-diagnostic subcohort interaction (P = 0.24). Abstinence rates with varenicline were superior to bupropion, NRT, and placebo, and abstinence with bupropion and NRT was superior to placebo. Within-diagnostic subcohort comparisons of treatment efficacy yielded estimated odds ratios for 9-12CAR versus placebo of greater than 3.00 for varenicline, greater than 1.90 for bupropion, and greater than 1.80 for NRT for all diagnostic groups. CONCLUSIONS Varenicline, bupropion, and nicotine patch are well tolerated and effective in adults with psychotic, anxiety, and mood disorders. The relative effectiveness of varenicline, bupropion, and NRT versus placebo did not vary across psychiatric diagnoses.
Collapse
Affiliation(s)
- A. Eden Evins
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Neal L. Benowitz
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Robert West
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Cristina Russ
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Thomas McRae
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - David Lawrence
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Alok Krishen
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Lisa St. Aubin
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Melissa Culhane Maravic
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| | - Robert M. Anthenelli
- Harvard Medical School and Massachusetts General Hospital Department of Psychiatry, Boston, Massachusetts, USA (AE Evins
, MC Maravic ); University of California
Department of Medicine, San Francisco, California, USA (NL Benowitz ); University College
Department of Behavioural Science and Health, London, UK (R West ); Pfizer, New York, New
York, USA (L St. Aubin , T McRae , D Lawrence
, C Russ ); PAREXEL International on behalf of
GSK, Research Triangle Park, North Carolina, USA (A Krishen ); Harvard Medical School and
Massachusetts General Hospital Division of Biostatistics, Boston, Massachusetts, USA );
Department of Psychiatry, University of California, San Diego, California, USA (RM Anthenelli
)
| |
Collapse
|
6
|
Ertekin H, Ertekin YH. The evaluation of the nicotine dependence in psychiatric disorders. KONURALP TIP DERGISI 2018. [DOI: 10.18521/ktd.365477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Rodríguez-Cano R, Paulus DJ, López-Durán A, Martínez-Vispo C, Fernández del Río E, Becoña E, Zvolensky MJ. The interplay of history of depression and craving in terms of smoking relapse among treatment seeking smokers. J Addict Dis 2017; 36:175-182. [DOI: 10.1080/10550887.2017.1314696] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Rubén Rodríguez-Cano
- Smoking and Addictive Disorders Unit, Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain
- Department of Psychology, University of Houston, Houston, Texas, USA
| | - Daniel J. Paulus
- Department of Psychology, University of Houston, Houston, Texas, USA
| | - Ana López-Durán
- Smoking and Addictive Disorders Unit, Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Carmela Martínez-Vispo
- Smoking and Addictive Disorders Unit, Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Elena Fernández del Río
- Smoking and Addictive Disorders Unit, Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain
- Department of Psychology and Sociology, Faculty of Social Sciences and Work, University of Zaragoza, Zaragoza, Spain
| | - Elisardo Becoña
- Smoking and Addictive Disorders Unit, Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Michael J. Zvolensky
- Department of Psychology, University of Houston, Houston, Texas, USA
- Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
8
|
Abstract
The high prevalence of cigarette smoking and tobacco related morbidity and mortality in people with chronic mental illness is well documented. This review summarizes results from studies of smoking cessation treatments in people with schizophrenia, depression, anxiety disorders, and post-traumatic stress disorder. It also summarizes experimental studies aimed at identifying biopsychosocial mechanisms that underlie the high smoking rates seen in people with these disorders. Research indicates that smokers with chronic mental illness can quit with standard cessation approaches with minimal effects on psychiatric symptoms. Although some studies have noted high relapse rates, longer maintenance on pharmacotherapy reduces rates of relapse without untoward effects on psychiatric symptoms. Similar biopsychosocial mechanisms are thought to be involved in the initiation and persistence of smoking in patients with different disorders. An appreciation of these common factors may aid the development of novel tobacco treatments for people with chronic mental illness. Novel nicotine and tobacco products such as electronic cigarettes and very low nicotine content cigarettes may also be used to improve smoking cessation rates in people with chronic mental illness.
Collapse
Affiliation(s)
- Jennifer W Tidey
- Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA
| | - Mollie E Miller
- Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA
| |
Collapse
|
9
|
Jamal M, Van der Does W, Penninx BWJH. Effect of variation in BDNF Val(66)Met polymorphism, smoking, and nicotine dependence on symptom severity of depressive and anxiety disorders. Drug Alcohol Depend 2015; 148:150-7. [PMID: 25618300 DOI: 10.1016/j.drugalcdep.2014.12.032] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Revised: 12/12/2014] [Accepted: 12/27/2014] [Indexed: 01/05/2023]
Abstract
BACKGROUND Smoking, especially nicotine dependence is associated with more severe symptoms of depression and anxiety disorders. However, the mechanisms underlying this association are unclear. We investigated the effect of brain-derived neurotrophic factor (BDNF) Val(66)Met polymorphism on the severity of depressive and anxiety symptoms in never-smokers, former smokers, non-dependent, and nicotine-dependent smokers with a current diagnosis of depression and/or anxiety. METHODS Patients with depressive or anxiety disorders and with available BDNF Val(66)Met polymorphism data (N=1271) were selected from Netherlands Study of Depression and Anxiety (NESDA). Dependent variables were severity of symptoms. Independent variables were smoking status and BDNF genotype. Age, sex, education, recent negative life events, alcohol use, body mass index, and physical activity were treated as covariates. RESULTS After controlling for covariates, nicotine-dependent smokers had more severe depressive symptoms than non-dependent smokers, former and never-smokers. The latter three groups did not differ in severity of depression. In Val(66)Val carriers, nicotine-dependent smokers had more severe symptoms of depression and anxiety than the other three groups, which were comparable in symptom severity. In Met(66) carriers, there were no group differences on severity of depression and anxiety. Nicotine dependence was the strongest predictor of severity of symptoms only in Val(66)Val carriers. CONCLUSIONS In patients with a current diagnosis of depression or anxiety, the relationship between nicotine dependence and symptom severity may be moderated by BDNF Val(66)Met. These results suggest that inherent genetic differences may be crucial for the worse behavioral outcome of nicotine, and that Val(66)Val carriers may benefit most in mental health from smoking cessation.
Collapse
Affiliation(s)
- Mumtaz Jamal
- Institute of Psychology, Leiden University, Wassenaarseweg 52, 2333 AK Leiden, The Netherlands.
| | - Willem Van der Does
- Institute of Psychology, Leiden University, Wassenaarseweg 52, 2333 AK Leiden, The Netherlands; Department of Psychiatry, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Brenda W J H Penninx
- Department of Psychiatry, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; Department of Psychiatry, VU University Medical Center, AJ Ernststraat 887, 1081 HL Amsterdam, The Netherlands; Department of Psychiatry, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
| |
Collapse
|
10
|
Utilization of evidence-based smoking cessation treatments by psychiatric inpatient smokers with depression. J Addict Med 2015; 8:77-83. [PMID: 24562400 DOI: 10.1097/adm.0000000000000027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Although smoking is a major health issue among depressed psychiatric inpatients and interest in quitting is high, successful quit rates remain low among this population. We sought to understand preferences that depressed inpatient smokers may have for cessation treatments. METHODS Eighty smokers (60% women, mean age 38.75 ± 11.20) with major depressive disorder and nicotine dependence receiving psychiatric inpatient services provided information on current depressive symptoms, smoking status and nicotine dependence, quit attempts, perceived barriers to quitting, and smoking consequences. RESULTS Almost half (46%) of participants endorsed a past-year quit attempt. Emotional barriers to quitting were uniquely associated with fewer past-year quit attempts, and depression severity was related to greater emotional barriers to quitting. Nicotine dependence severity was related to a variety of emotional, financial, weight concern, and self-efficacy barriers, but only weight gain concern was associated with decreased odds of making a past-year quit attempt. The number of lifetime quit attempts was positively associated with negative smoking consequences. With regard to interest in smoking cessation treatment, 86% and 92% of smokers reported a willingness to try behavioral counseling and nicotine replacement products, respectively, but fewer smokers reported a willingness to try medication, print or Web-based materials, or an unaided quit attempt. CONCLUSIONS Although half of our sample reported recent quit attempts, many people did not make an attempt using an evidence-based treatment. On the basis of consumer preferences identified herein, clinical recommendations for reinforcing the use of evidence-based smoking cessation treatments for depressed psychiatric inpatient smokers are provided.
Collapse
|
11
|
Goodwin RD, Sheffer CE, Chartrand H, Bhaskaran J, Hart CL, Sareen J, Bolton J. Drug Use, Abuse, and Dependence and the Persistence of Nicotine Dependence. Nicotine Tob Res 2014; 16:1606-12. [DOI: 10.1093/ntr/ntu115] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
12
|
Smoking and suicidality in subjects with major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Affect Disord 2013; 150:1158-66. [PMID: 23827531 DOI: 10.1016/j.jad.2013.05.082] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Accepted: 05/24/2013] [Indexed: 11/22/2022]
Abstract
BACKGROUND Detailed characteristics of depressive smokers and its association with suicidality were still less investigated. The aim of this study was to delineate characteristics of smokers with major depressive disorder (MDD) and examine the relationship between these characteristics and suicidality using an epidemiologic database, the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). METHODS A total of 5695 subjects with MDD, defined by the DSM-IV criteria, were included in our analysis. Current smokers, former smokers, and lifetime nonsmokers were compared in terms of demographic, clinical characteristics, and functional level. Suicidality, evaluated by history of suicide ideation and attempts while in a low mood was evaluated and compared among the groups. RESULTS Current smokers with MDD showed a greater number of DSM-IV symptoms while in acute episodes, a higher rate of alcohol and drug-use disorders, and poorer functional levels than nonsmokers. Previous smokers displayed intermediate characteristics between current smokers and nonsmokers. The logistic regression analysis revealed that both current and former smoking status predicted the risk of having a history of attempted suicide (current smokers: odds ratio 1.62, 95% C.I. 1.42-1.86; former smokers: odds ratio 1.37, 95% C.I. 1.13-1.66) after adjusting for demographic data, a history of subthreshold hypomania, and a lifetime axis II/anxiety/alcohol use/substance-use disorder. LIMITATIONS Retrospective, cross-sectional evaluation; suicidality assessed only in the most severe depressive episode. CONCLUSIONS The present study corroborates that smokers with MDD showed distinct clinical characteristics, and cigarette smoking can predict attempted suicide in a community representative sample of people with MDD.
Collapse
|
13
|
Payne TJ, Ma JZ, Crews KM, Li MD. Depressive symptoms among heavy cigarette smokers: the influence of daily rate, gender, and race. Nicotine Tob Res 2013; 15:1714-21. [PMID: 23569006 DOI: 10.1093/ntr/ntt047] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
INTRODUCTION Cigarette smokers experience higher levels of depressive symptoms and are more likely to be diagnosed with depressive disorders than nonsmokers. To date, the nature of the smoking-depression relationship has not been adequately studied among heavy smokers, a group at elevated risk for poor health outcomes. In this study, we examined depressive symptom expression among heavy smokers while considering the moderating roles of smoking status, gender, and race. We also explored whether amount of tobacco usually consumed had an impact. METHODS We extracted data from a large, highly nicotine-dependent, nontreatment cigarette smoking study sample (N = 6,158). Participants who consented were screened for major exclusions, and they completed questionnaires. RESULTS Smokers reported a higher, clinically meaningful level of depressive symptoms relative to nonsmokers (27.3% of smokers vs. 12.5% of nonsmokers) scored above the clinical cutoff on the Center for Epidemiological Studies Depression (CES-D) scale (p < .001), which differed among race × gender subgroups. Further, amount of daily intake was inversely associated with self-report of depressive symptoms. For every 10-cigarette increment, the likelihood of scoring above the CES-D clinical cutoff decreased by 62% (p < .0001). CONCLUSIONS These findings improve our understanding of tobacco's influence on depressive symptom expression among heavy smokers, with implications for tailoring evidence-based tobacco treatments.
Collapse
Affiliation(s)
- Thomas J Payne
- Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, MS
| | | | | | | |
Collapse
|
14
|
Association of smoking and nicotine dependence with severity and course of symptoms in patients with depressive or anxiety disorder. Drug Alcohol Depend 2012; 126:138-46. [PMID: 22633368 DOI: 10.1016/j.drugalcdep.2012.05.001] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2012] [Revised: 05/02/2012] [Accepted: 05/03/2012] [Indexed: 11/22/2022]
Abstract
BACKGROUND Previous research has indicated a strong association of smoking with depression and anxiety disorders, but the direction of the relationship is uncertain. Most research has been done in general population samples. We investigated the effect of smoking and nicotine dependence on the severity and course of depressive and anxiety symptoms in psychiatric patients. METHODS Data came from the Netherlands Study of Depression and Anxiety (NESDA) including participants with a current diagnosis of depression and/or an anxiety disorder (N=1725). The course of smoking status and symptoms of depression, general anxiety, social anxiety, and agoraphobia were measured at baseline and after one and two years. Age, gender, education, alcohol use, physical activity, and negative life events were treated as covariates. RESULTS At baseline, the symptoms of depression, general anxiety, and agoraphobia were more severe in nicotine-dependent smokers than in never-smokers, former smokers, and non-dependent smokers. These differences remained after adjusting for covariates. Smaller differences were observed for severity of social anxiety which were no longer significant after controlling for covariates. Over a two-year follow-up, the improvement of depressive and anxiety symptoms was slower in nicotine-dependent smokers than in the other groups even after controlling for covariates. There were no differences between the groups in the course of symptoms of social anxiety and agoraphobia over time. CONCLUSIONS In psychiatric patients, smoking is associated with higher severity of depressive and anxiety symptoms, and with slower recovery, but only when smokers are nicotine-dependent.
Collapse
|
15
|
Strong DR, Schonbrun YC, Schaffran C, Griesler PC, Kandel D. Linking measures of adult nicotine dependence to a common latent continuum and a comparison with adolescent patterns. Drug Alcohol Depend 2012; 120:88-98. [PMID: 21855236 PMCID: PMC3540800 DOI: 10.1016/j.drugalcdep.2011.07.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Revised: 05/20/2011] [Accepted: 07/03/2011] [Indexed: 11/19/2022]
Abstract
BACKGROUND An ongoing debate regarding the nature of nicotine dependence (ND) is whether the same instrument can be applied to measure ND among adults and adolescents. Using a hierarchical item response model (IRM), we examined evidence for a common continuum underlying ND symptoms among adults and adolescents. METHOD The analyses are based on two waves of interviews with subsamples of parents and adolescents from a multi-ethnic longitudinal cohort of one thousand and thirty-nine 6-10th graders from the Chicago Public Schools (CPS). Adults and adolescents who reported smoking cigarettes the last 30 days prior to waves 3 and 5 completed three common instruments measuring ND symptoms and one item measuring loss of autonomy. RESULTS A stable continuum of ND, first identified among adolescents, was replicated among adults. However, some symptoms, such as tolerance and withdrawal, differed markedly across adults and adolescents. The majority of mFTQ items were observed within the highest levels of ND, the NDSS items within the lowest levels, and the DSM-IV items were arrayed in the middle and upper third of the continuum of dependence severity. Loss of autonomy was positioned at the lower end of the continuum. We propose a ten-symptom measure of ND for adolescents and adults. CONCLUSIONS Despite marked differences in the relative severity of specific ND symptoms in each group, common instrumentation of ND can apply to adults and adolescents. The results increase confidence in the ability to describe phenotypic heterogeneity in ND across important developmental periods.
Collapse
Affiliation(s)
- David R Strong
- Brown University, Butler Hospital, Providence, RI 2906, United States. david
| | | | | | | | | |
Collapse
|
16
|
Gili M, Garcia-Toro M, Vives M, Armengol S, Garcia-Campayo J, Soriano JB, Roca M. Medical comorbidity in recurrent versus first-episode depressive patients. Acta Psychiatr Scand 2011; 123:220-7. [PMID: 21118188 DOI: 10.1111/j.1600-0447.2010.01646.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE This study compares the comorbidity of affective disorders and medical diseases in primary care patients with either a first or recurrent depressive episode. METHOD A cross-sectional epidemiological study in primary care centres in Spain was designed. A total of 10,257 primary care patients suffering a DSM-IV major depressive episode (MDD) were analysed. Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS), and World Health Organization (WHO) medical diagnoses were provided by the patient's general practitioner according to medical records revised on the basis of radiology or laboratory test data. RESULTS A total of 88.6% of recurrent patients and 71.1% of first-episode depressive patients reported a medical condition (aOR = 2.61, CI = 2.31-2.93). All medical conditions were more prevalent in the recurrent group than in first-episode group, and with the exception of myocardial infarction, psoriasis and migraine, all other crude ORs showed statistically significant differences between first- and recurrent episodes patients after adjusting for gender, age, education, socioeconomic status and body mass index (BMI). CONCLUSION Recurrent depression is associated with a decrement in health that is significantly greater than in first-episode depression. Special attention needs to be paid to the physical health in the middle- and long-term management of patients with affective disorders.
Collapse
Affiliation(s)
- M Gili
- Institut Universitari d'Investigació en Ciències de Salut, University of Balearic Islands, Palma de Mallorca, Spain.
| | | | | | | | | | | | | |
Collapse
|
17
|
Kandi P, Hayslett R. Nicotine and 17β-estradiol produce an antidepressant-like effect in female ovariectomized rats. Brain Res Bull 2011; 84:224-8. [DOI: 10.1016/j.brainresbull.2010.12.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Revised: 12/17/2010] [Accepted: 12/20/2010] [Indexed: 10/18/2022]
|